MedPath

Evaluation of Safety and Tolerability of HOAW-062101 in Healthy Adults

Phase 1
Registration Number
CTRI/2023/03/051001
Lead Sponsor
Himalaya Wellness Company
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Healthy adult subjects of either sex aged between >=18 to <=50 years.

2. Subjects willing to sign informed consent and follow the study procedure.

3. Has not participated in a similar investigation in the past four weeks.

4. Subjects willing to refrain taking any other similar supplements during the study period

Exclusion Criteria

1.Subjects with clinically significant serious cardiovascular, cerebrovascular, respiratory, liver, renal disease, congenital or any other disorder.

2.Subjects with any abnormal lab values detected at screening shall be excluded.

3.A known history or present condition of allergic response to pharmaceutical products its components or ingredients in the investigational products (IP).

4.Pre-existing systemic disease necessitating long-term medications.

5.Genetic and endocrinal disorders.

6.Subjects who refused to sign informed consent.

7.Pregnant and lactating women.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of any adverse or serious adverse events reported or observed during the study period for 7 daysTimepoint: Incidence of any adverse or serious adverse events reported or observed during the study period for 7 days
Secondary Outcome Measures
NameTimeMethod
Overall compliance of the subject to the study medicationTimepoint: 7 days
© Copyright 2025. All Rights Reserved by MedPath